Pathogenesis-based and nephroprotective therapeutic approaches

Immunoglobulin (Ig) A nephropathy is considered an important cause of end-stage renal failure. Therefore, from today’s perspective, IgA nephropathy should not be classified as a benign disease. Fortunately, the treatment spectrum has expanded in recent years. In addition to oral TRF-budesonide and the DEARA drug sparsentan, which have now been approved in many countries, numerous pathogenesis-based therapies are currently in development. However, classic nephroprotective therapy options – RAAS-i, SGLT-2-i, MRA and GLP-1-RA – also continue to play an important role .